Fenofibrate and Pharmacogenetic Impact in Dyslipidemia
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to learn whether genetics plays a role in predicting response to
a commonly used and FDA (Food and Drug Administration) approved medication for lowering
triglycerides and cholesterol. The hypothesis: The pharmacogenetics of genes which affect
drug metabolism (how the body handles the drug) and drug targets (how the drug acts on the
body) influences how a person responds to the lipid lowering medication-fenofibrate.
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute